Marco Passini, Ph.D.

Marco Passini, Ph.D., vice president and head of CNS biology at Korro Bio, brings 20 years of biotechnology experience developing gene and oligonucleotide therapies for CNS and muscle disorders.

Marco was previously senior director of pharmacology at Disarm Therapeutics where he led the oligonucleotide program for ALS, and director of biology at Sarepta where he worked with multiple functional teams to bring next-generation oligonucleotides for Duchenne muscular dystrophy to the clinic.

Marco began his biotechnology career at Genzyme where he successfully led pre-clinical CNS research programs, including collaborating with academic and biotech partners to help bring therapies to the clinic including gene therapy for Batten disease and the FDA-approved Spinraza® for SMA.

Marco received a Ph.D. in molecular biology and biochemistry from the State University of New York at Stony Brook, followed by a postdoctoral fellowship in neurodegeneration at the University of Pennsylvania.